BioVersys AGCHIX:BIOVZ 14 EBITDA Margin % is -1,264.75% as of Dec. 2025. GuruFocus rates CHIX:BIOVZ with a GF Score™ of 14/100. Among 936 Biotechnology companies, BioVersys AG ranks worse than 86.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioVersys AG's EBITDA for the
six
months ended in Dec. 2025 was CHF-10.12 Mil. BioVersys AG's Revenue for the
six
months ended in Dec. 2025 was CHF0.80 Mil. Therefore, BioVersys AG's EBITDA margin for the quarter that ended in Dec. 2025 was -1,264.75%.
BioVersys AG (CHIX:BIOVz) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioVersys AG EBITDA Margin % Related Terms
BioVersys AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BioVersys AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG EBITDA Margin % Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
EBITDA Margin %
0.00
-2,555.00
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
EBITDA Margin %
0.00
0.00
0.00
-1,264.75
CHIX:BIOVZ vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, BioVersys AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioVersys AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (CHIX:BIOVZ) has a EBITDA Margin % of -1,264.75% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #807 out of 936 companies in the Biotechnology industry, placing it in the top 86.2%.
Is BioVersys AG's EBITDA Margin % too high?
BioVersys AG's current EBITDA Margin % is -1,264.75%. Based on the distribution chart, BioVersys AG ranks #807 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #807 out of 936 companies for EBITDA Margin %. This places BioVersys AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioVersys AG and its competitors. BioVersys AG's current EBITDA Margin % is -1,264.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (CHIX:BIOVZ) has a current EBITDA Margin % of -1,264.75%. The current EBITDA Margin % is -1,264.75%. BioVersys AG's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioVersys AG (CHIX:BIOVZ), the current EBITDA Margin % is -1,264.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
14GF Score
Get the complete analysis for CHIX:BIOVZ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BIOVZ has been successfully added to your 